Editing Abbott Laboratories (section)

==History==
{{anchor|Wallace Abbott}}

[[File:Dr. Wallace C. Abbott.jpg|thumb|right|Dr. Wallace C. Abbott]]

=== Foundation and early history ===
{{See also|Dr. Wallace C. Abbott House}}
In 1888 at the age of 30, Wallace Abbott (1857–1921), an 1885 graduate of the [[University of Michigan]], founded the '''Abbott Alkaloidal Company''' in [[Ravenswood, Chicago]]. At the time, he was a practising physician and owned a drug store. His innovation was formulating the active part of [[alkaloid]]  [[Herbalism|medicinal plants]]—[[morphine]], [[quinine]], [[strychnine]] and [[codeine]]—as tiny "dosimetric granules", producing more consistent and effective dosages for patients than the liquid preparations previously used, which deteriorated over time.<ref>{{cite web |url=http://www.fundinguniverse.com/company-histories/Abbott-Laboratories-Company-History.html |title=Abbott Laboratories Company History |publisher=Funding Universe |access-date=17 April 2013 |archive-date=2 June 2012 |archive-url=https://web.archive.org/web/20120602214830/http://www.fundinguniverse.com/company-histories/Abbott-Laboratories-Company-History.html |url-status=live }}</ref> In 1922, the company moved from Ravenswood to [[North Chicago, Illinois]].{{citation needed|date=December 2022}}

=== International expansion ===
Abbott's first international affiliate was in London in 1907; the company later added an affiliate in Montreal, Canada.{{citation needed|date=June 2020}} Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, and to Boots Pharmaceuticals Ltd on January 1, 1991. On October 31, 1995, the name was changed to Knoll Pharmaceuticals Ltd and on July 1, 2002, to their present name Abbott India Ltd. Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has steadily expanded to comprise a work force of over 1500 employees. Currently, two manufacturing facilities located at Landhi and Korangi in [[Karachi]] continue to produce pharmaceutical products.<ref>{{Cite web|url=https://www.pk.abbott/homepage.html|title=Abbott in Pakistan &#124; Abbott|website=www.pk.abbott|access-date=5 July 2023|archive-date=18 June 2021|archive-url=https://web.archive.org/web/20210618065938/https://www.pk.abbott/homepage.html|url-status=live}}</ref> In 1962  Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radio-pharmaceuticals.{{citation needed|date=June 2020}} In 1964, it merged with Ross Laboratories, making Ross a wholly owned subsidiary of Abbott, and Richard Ross gained a seat on Abbott's board of directors until his retirement in 1983.<ref>{{cite web|url=https://www.chicagotribune.com/news/ct-xpm-1993-12-11-9312110107-story.html|title=RICHARD MOORE ROSS, 77, ABBOTT LABS EXECUTIVE|first=Chicago|last=Tribune|website=Chicago Tribune|date=11 December 1993|access-date=2 June 2019|archive-date=30 September 2022|archive-url=https://web.archive.org/web/20220930075607/https://www.chicagotribune.com/news/ct-xpm-1993-12-11-9312110107-story.html|url-status=live}}</ref> The acquisition of Ross brought Similac under the Abbott umbrella. In the years following the acquisition, Pedialyte and Ensure were introduced as nutritional products by Ross Laboratories while under Abbott's leadership.<ref>{{Cite web |url=https://ohiohistorycentral.org/w/Ross_Laboratories |title=Ross Laboratories - Ohio History Central |website=ohiohistorycentral.org |access-date=2020-04-02 |archive-date=30 September 2022 |archive-url=https://web.archive.org/web/20220930000742/https://ohiohistorycentral.org/w/Ross_Laboratories |url-status=live }}</ref><ref>{{Cite web |url=https://www.dispatch.com/business/20190222/abbott-labs-plans-62-million-investment-in-columbus |title=Abbott Labs plans $62 million investment in Columbus |last=Rose |first=Marla Matzer |website=The Columbus Dispatch |language=en |access-date=2020-04-02 |archive-date=20 August 2020 |archive-url=https://web.archive.org/web/20200820173356/https://www.dispatch.com/business/20190222/abbott-labs-plans-62-million-investment-in-columbus |url-status=dead }}</ref><ref>{{Cite web |url=https://oilcity.news/general/2020/01/10/welcome-sherri-blanchard-m-d-to-douglas-primary-care/ |title=Welcome Sherri Blanchard, M.D., to Douglas Primary Care – Casper, WY Oil City News |date=2020-01-10 |website=Oil City News |language=en-US |access-date=2020-04-02 |archive-date=29 November 2022 |archive-url=https://web.archive.org/web/20221129201413/https://oilcity.news/general/2020/01/10/welcome-sherri-blanchard-m-d-to-douglas-primary-care/ |url-status=live }}</ref>

In 1965, Abbott's expansion in Europe continued with offices in Italy and France.{{citation needed|date=December 2022}}

According to Harvard professor [[Lester Grinspoon]] and Peter Hedblom, "In 1966 Abbott Laboratories sold the equivalent of two million doses of [[methamphetamine]] in powder form to a Long Island criminal dealer".<ref name="grinspoon23">{{cite book|last1=Grinspoon|first1=Lester|last2=Hedblom|first2=Peter|title=The Speed Culture: Amphetamine Use and Abuse in America|date=1975|publisher=Harvard University Press|location=Cambridge, Massachusetts|isbn=9780674831926|oclc=1362148|page=[https://archive.org/details/speedcultureamph0000grin_n3i0/page/23 23]|url=https://archive.org/details/speedcultureamph0000grin_n3i0|url-access=registration|quote=strasenburgh prescription.}}</ref>

In 1985, Abbott partnered with the Japanese company [[Taisho Pharmaceutical]] for the international rights to [[clarithromycin]], a second-generation [[macrolide]] [[antibiotic]], and gained FDA approval for the drug under the brand name Biaxin in October 1991. The drug went [[Generic drug|generic]] in Europe in 2004 and in the US in mid-2005,<ref name="pmid25165548">{{cite journal | vauthors = Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A | title = Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports | journal = Therapeutic Advances in Infectious Disease | volume = 1 | issue = 4 | pages = 121–138 | date = August 2013 | pmid = 25165548 | pmc = 4040724 | doi = 10.1177/2049936113497203 }}</ref> and has been added to the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO-2019">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref>

=== 21st century ===
In 2001, the company acquired Knoll, the pharmaceutical division of [[BASF]], for $6.9&nbsp;billion.<ref>{{Cite news |url=https://www.chicagotribune.com/2001/03/03/abbott-closes-early-on-knoll-acquisition/ |title=Abbott Closes Early On Knoll Acquisition |date=March 3, 2001 |work=Chicago Tribune}}</ref> In 2002, it divested the [[Selsun Blue]] brand to [[Chattem]].<ref>{{Cite news |url=https://www.nytimes.com/2002/03/06/business/company-news-chattem-buys-selsun-blue-shampoo-brand-from-abbott.html |title=Company News; Chattem Buys Selsun Blue Shampoo Brand From Abbott |date=March 6, 2002 |work=The New York Times |agency=Reuters |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070500/https://www.nytimes.com/2002/03/06/business/company-news-chattem-buys-selsun-blue-shampoo-brand-from-abbott.html |url-status=live }}</ref> Later in 2002, it sold [[Clear Eyes]] and Murine brands to [[Prestige Brands]].<ref>{{Cite web |last=Smith |first=Scott S. |date=January 11, 2018 |title=Miles White's Bold Moves Made Abbott Laboratories A Global Force |url=https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |work=Investor's Business Daily |access-date=25 December 2018 |archive-date=20 November 2021 |archive-url=https://web.archive.org/web/20211120121814/https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |url-status=live }}</ref> In 2004,  it acquired TheraSense, a [[diabetes]]-care company, which it merged with its MediSense division to become Abbott Diabetes Care.<ref>{{Cite news |last=Sandred |first=Jan |date=January 14, 2004 |title=$1 billion medical deal / Abbott Labs to buy Therasense, maker of glucose monitors |url=https://www.sfgate.com/bayarea/article/1-billion-medical-deal-abbott-labs-to-buy-2812649.php |work=SFGATE |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.sfgate.com/bayarea/article/1-billion-medical-deal-abbott-labs-to-buy-2812649.php |url-status=live }}</ref>{{additional citation needed|date=June 2020}} In 2006, Abbott assisted [[Boston Scientific]] in its purchase of [[Guidant]] Corporation purchasing the vascular device division of Guidant.<ref>{{Cite news |last1=Feder |first1=Barnaby |last2=Sorkin |first2=Andrew Ross |date=January 18, 2006 |title=Boston Scientific, With Abbott's Help, Raises Bid for Guidant |url=https://www.nytimes.com/2006/01/18/business/boston-scientific-with-abbotts-help-raises-bid-for-guidant.html |work=The New York Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.nytimes.com/2006/01/18/business/boston-scientific-with-abbotts-help-raises-bid-for-guidant.html |url-status=live }}</ref><ref>{{Cite news |last=Feder |first=Barnaby |date=September 27, 2006 |title=Johnson & Johnson Sues Boston Scientific, Guidant and Abbott Laboratories Over Deal |url=https://www.nytimes.com/2006/09/27/business/27device.html |work=The New York Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070500/https://www.nytimes.com/2006/09/27/business/27device.html |url-status=live }}</ref>

In 2007, Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash.<ref>{{cite news |last=Smith |first=Scott S. |date=11 January 2018 |title=Miles White's Bold Moves Made Abbott Laboratories A Global Force |url=https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |work=Investor's Business Daily |access-date=25 December 2018 |archive-date=20 November 2021 |archive-url=https://web.archive.org/web/20211120121814/https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |url-status=live }}</ref> At the time of acquisition Kos marketed Niaspan (extended release [[niacin (substance)|niacin]]), and Advicor ([[niacin/lovastatin]]).

In 2007 the company was to sell two diagnostics divisions to [[General Electric]], but the parties did not agree on the terms of the acquisition.<ref>{{cite news | last1=Layne | first1=Rachel | last2=Lopatto | first2=Elizabeth | url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLKvFFqD3DQw | title=GE, Abbott End $8.13 Billion Diagnostic Sale Deal (Update2) | agency=Bloomberg News | date=11 July 2007 | access-date=5 March 2017 | archive-date=24 September 2015 | archive-url=https://web.archive.org/web/20150924153211/http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLKvFFqD3DQw | url-status=live }}</ref>

On 8 September 2007, the company sold the UK manufacturing plant at [[Queenborough]] to UK manufacturer Aesica Pharmaceuticals.<ref>{{Cite web |url=https://www.pharmaceutical-technology.com/projects/aesicasnewcontainmen/ |title=Aesica Containment Facility |date=November 7, 2013 |website=Pharmaceutical Technology |access-date=10 March 2024 |archive-date=7 June 2023 |archive-url=https://web.archive.org/web/20230607023207/https://www.pharmaceutical-technology.com/projects/aesicasnewcontainmen/ |url-status=live }}</ref><ref>{{Cite news |last=Tighe |first=Chris |date=July 8, 2007 |title=Aesica seizes some bargain buys |url=https://www.ft.com/content/9b5346fe-2d66-11dc-939b-0000779fd2ac |work=Financial Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.ft.com/content/9b5346fe-2d66-11dc-939b-0000779fd2ac |url-status=live }}</ref>

Abbott's Ross Products was renamed Abbott Nutrition in 2007.<ref>{{Cite web |last=Wilson |first=Paul |title=End of an era: Abbott retires Ross Products name |url=https://www.dispatch.com/story/news/2007/11/08/end-era-abbott-retires-ross/24057637007/ |access-date=2020-04-02 |website=The Columbus Dispatch |language=en}}</ref>

In 2009 Abbott acquired [[Advanced Medical Optics]] of [[Santa Ana, California]], selling it to [[Johnson & Johnson]] in 2017.<ref>{{cite web|url=https://www.ocregister.com/2017/02/28/johnson-johnson-completes-43b-acquisition-of-abbott-medical-optics-in-santa-ana/|title=Johnson & Johnson completes $4.3B acquisition of Abbott Medical Optics in Santa Ana|website=Orange County Register|date=28 February 2017|access-date=22 November 2019|archive-date=2 December 2022|archive-url=https://web.archive.org/web/20221202033619/https://www.ocregister.com/2017/02/28/johnson-johnson-completes-43b-acquisition-of-abbott-medical-optics-in-santa-ana/|url-status=live}}</ref> In 2009, Abbott opened a satellite research and development facility at [[Research Park, University of Illinois at Urbana-Champaign]].<ref>{{cite web|url=https://www.news-gazette.com/news/abbott-labs-leasing-space-in-ui-research-park/article_daf381df-df4d-5516-90c8-9ef89ed56d36.html|title=Abbott Labs leasing space in UI research park|website=The News Gazette|date=2 May 2009|access-date=22 November 2019|archive-date=20 November 2022|archive-url=https://web.archive.org/web/20221120024440/https://www.news-gazette.com/news/abbott-labs-leasing-space-in-ui-research-park/article_daf381df-df4d-5516-90c8-9ef89ed56d36.html|url-status=live}}</ref>

In February 2010, Abbott acquired the pharmaceuticals unit of [[Solvay S.A.]] for [[US$]]6.2 billion ([[€]]4.5 billion),<ref>{{cite web|url=http://www.abbott.com/news-media/press-releases/Press_Release_0819.htm |title=Abbott Completes Acquisition of Solvay Pharmaceuticals |author=Abbott Press Release |date=16 February 2010 |access-date=22 March 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120312235321/http://www.abbott.com/news-media/press-releases/Press_Release_0819.htm |archive-date=12 March 2012 }}</ref> gaining many additional pharmaceutical products and an increased presence in emerging markets.<ref name="Abbott-Feb-2010-8-K">{{cite web |url=http://pdf.secdatabase.com/205/0001104659-10-007120.pdf |title=Abbott Laboratories Feb 2010 Current Report, Form 8-K, Filing Date Feb 16, 2010 |publisher=secdatabase.com |access-date=27 December 2012 |archive-date=23 May 2013 |archive-url=https://web.archive.org/web/20130523222642/http://pdf.secdatabase.com/205/0001104659-10-007120.pdf |url-status=live }}</ref>

In 2010 the company acquired [[Hollywood, Florida]]-based [[laboratory information management system]] company [[STARLIMS]] for $123 million, $14 per share.<ref>{{Cite news |url=https://www.chicagotribune.com/2009/12/15/abbott-sets-deal-to-buy-starlims/ |title=Abbott sets deal to buy Starlims |date=December 15, 2009 |work=Chicago Tribune |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.chicagotribune.com/2009/12/15/abbott-sets-deal-to-buy-starlims/ |url-status=live }}</ref><ref>{{Cite press release |url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-starlims-technologies-88846137.html |title=Abbott Completes Acquisition of STARLIMS Technologies |date=March 22, 2010 |publisher=PR Newswire}}</ref> That year Abbott said it would buy [[Piramal Group|Piramal Healthcare]] of India's large generic drugs unit for $3.72 billion.<ref>{{cite news|url=https://www.wsj.com/articles/SB10001424052748704852004575257614197847830|title=Abbott Labs to Buy Indian Business|author=Peter Loftus and Rumman Ahmed|work=The Wall Street Journal|access-date=26 September 2019|archive-date=5 August 2023|archive-url=https://web.archive.org/web/20230805093503/http://www.wsj.com/articles/SB10001424052748704852004575257614197847830|url-status=live}}</ref><ref>Abbott 2011 annual report, p43</ref>

=== Spin-offs ===
In 2004, Abbott spun off its hospital products division into a new 14,000 employee company, [[Hospira]],<ref>{{Cite web |url=https://www.bizjournals.com/austin/stories/2004/01/26/story3.html |title=Abbott Labs to spin off unit |last=Higginbotham |first=Stacey |date=2004-01-25 |website=The Business Journals |access-date=2020-04-02 |archive-date=14 January 2016 |archive-url=https://web.archive.org/web/20160114210453/http://www.bizjournals.com/austin/stories/2004/01/26/story3.html |url-status=live }}</ref> which was acquired by [[Pfizer]] in 2015.<ref>{{Cite web |url=https://marketrealist.com/2016/09/pfizers-hospira-deal-catching-up-a-year-later/ |title=Pfizer's Hospira Deal: Catching Up a Year Later |last=Dabney |first=Jillian |date=2016-09-09 |website=Market Realist |language=en-US |access-date=2020-04-02 |archive-date=28 September 2022 |archive-url=https://web.archive.org/web/20220928145919/https://marketrealist.com/2016/09/pfizers-hospira-deal-catching-up-a-year-later/ |url-status=live }}</ref>

In October 2011, Abbott planned to separate into two companies, one for research-based pharmaceuticals ([[AbbVie]]) and the other for medical devices, generic drugs sold internationally, and diagnostics, with the latter retaining the Abbott name.<ref name=nyt>{{cite news|url=https://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two|title=Abbott Labs to Split into 2 Companies|first1=Michael|last1=de La Mercedfirst2=Bruce|last2=Japsen|newspaper=The New York Times|date=19 October 2011|access-date=26 September 2019|archive-date=17 June 2022|archive-url=https://web.archive.org/web/20220617065658/https://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two/|url-status=live}}</ref><ref>{{cite news|last1=Rockoff|first1=Jonathan D.|title=Abbott to Split into Two Companies|url=https://www.wsj.com/articles/SB10001424052970204485304576640740820288766|work=[[The Wall Street Journal]]|date=20 October 2011|access-date=5 March 2017|archive-date=12 December 2022|archive-url=https://web.archive.org/web/20221212040813/http://www.wsj.com/articles/SB10001424052970204485304576640740820288766|url-status=live}}</ref> Abbott Nutrition, whose products include Similac, Pedialyte, Glucerna, and Ensure, also retained the Abbott name.<ref name=nyt /> In preparation for the reorganization, Abbott made severe budget cuts and took a $478 million charge in Q3-2012.<ref name=frost2012>{{Citation |author=Frost, Peter |date=17 October 2012 |title=Abbott lays off 550 |newspaper=[[Chicago Tribune]] |url=http://www.chicagotribune.com/business/breaking/chi-abbott-lays-off-550-20121017,0,4039023.story |access-date=16 November 2012 |archive-url=https://web.archive.org/web/20121019011529/http://www.chicagotribune.com/business/breaking/chi-abbott-lays-off-550-20121017,0,4039023.story |archive-date=19 October 2012 |url-status=dead }}</ref> The separation was effective as of 1 January 2013, and AbbVie was listed in the [[New York Stock Exchange]].<ref>{{cite news|last1=Armstrong|first1=Drew|title=AbbVie Rises on First Day of Trading After Abbott Spinoff|url=https://www.bloomberg.com/news/articles/2013-01-02/abbvie-rises-on-first-day-of-trading-after-abbott-spinoff|work=Bloomberg News|date=2 January 2013|access-date=5 March 2017|archive-date=30 March 2022|archive-url=https://web.archive.org/web/20220330020520/https://www.bloomberg.com/news/articles/2013-01-02/abbvie-rises-on-first-day-of-trading-after-abbott-spinoff|url-status=live}}</ref>

=== Further developments ===
On 16 May 2014, it was announced that Abbott would acquire the [[holding company]] Kalo Pharma Internacional S.L. for $2.9 billion in order to secure the 73% it held of Chilean pharmaceutical company, [[CFR Pharmaceuticals]], which the company said would more than double its branded generic drug portfolio.<ref name=":0" /><ref>{{cite web|url=https://www.bloomberg.com/news/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceuticals.html|title=Abbott to acquire CFR Pharmaceuticals|author=Bloomberg Release|website=[[Bloomberg News]]|date=16 May 2014|access-date=16 May 2014|archive-date=19 December 2014|archive-url=https://web.archive.org/web/20141219070557/http://www.bloomberg.com/news/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceuticals.html|url-status=live}}</ref><ref>{{Cite news|title=Abbott Grows Branded Generics with $3.3B CFR Acquisition|last=Staff|date=15 June 2014|work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|issue=12|department=News {{!}} Industry Watch|volume=34|page=8|type=Paper}}</ref>

In December 2014, the company acquired Russian pharmaceutical manufacturer Veropharm ([[Voronezh]]) in a deal worth $410 million, which included three manufacturing facilities.<ref name=":0" /><ref>{{cite web|url=https://www.forbes.com/sites/greatspeculations/2014/06/24/abbott-acquires-veropharm-to-expand-presence-in-russia/|title=Abbott Acquires Veropharm To Expand Presence in Russia|website=Forbes|access-date=17 October 2019|archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820173042/https://www.forbes.com/sites/greatspeculations/2014/06/24/abbott-acquires-veropharm-to-expand-presence-in-russia/|url-status=live}}</ref> Abbott, which already employed 1,400 people in Russia, said it planned to set up a manufacturing presence in the country when the deal closed.<ref>{{cite web|url=https://www.reuters.com/finance/stocks/ABT/key-developments|archive-url=https://web.archive.org/web/20110825120828/http://www.reuters.com/finance/stocks/ABT/key-developments|url-status=dead|archive-date=2011-08-25|title=Abbott Laboratories (ABT) Key Developments |work=Reuters.com}}</ref>

In September 2015, the company announced it had completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies.<ref name=autogenerated1>{{Cite web|url=https://abbott.mediaroom.com/2015-09-02-Abbott-Completes-Acquisition-of-Tendyne-Holdings-Inc|title=Abbott Completes Acquisition of Tendyne Holdings, Inc. – Sep 2, 2015|website=Abbott MediaRoom|language=en-us|access-date=2020-02-02|archive-date=21 July 2023|archive-url=https://web.archive.org/web/20230721231449/https://abbott.mediaroom.com/2015-09-02-Abbott-Completes-Acquisition-of-Tendyne-Holdings-Inc|url-status=live}}</ref> Tendyne was acquired for a total transaction value of $250 million.<ref name=autogenerated1 /> In January 2020, the Tendyne Mitral Valve became the world's first commercially available solution for Mitral Valve Replacement Technology.{{citation needed|date=June 2020}} Abbott obtained CE Mark for the device which now makes it possible to implant it in Europe outside of a clinical setting. The US clinical study for federal approval is still ongoing.<ref>{{Cite web|url=https://abbott.mediaroom.com/2020-01-30-Abbotts-Tendyne-TM-Device-Receives-Worlds-First-CE-Mark-for-Transcatheter-Mitral-Valve-Implantation|title=Abbott's Tendyne Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation – Jan 30, 2020|website=Abbott MediaRoom|language=en-us|access-date=2020-02-02|archive-date=14 August 2023|archive-url=https://web.archive.org/web/20230814195332/https://abbott.mediaroom.com/2020-01-30-Abbotts-Tendyne-TM-Device-Receives-Worlds-First-CE-Mark-for-Transcatheter-Mitral-Valve-Implantation|url-status=live}}</ref>

In February 2016, the company announced it would acquire [[Alere]] for $5.8 billion.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/abbott-to-acquire-alere-for-5-8b/81252306/|title=Abbott to Acquire Alere for $5.8B|work=GEN|date=February 2016|access-date=1 February 2016|archive-date=2 February 2016|archive-url=https://web.archive.org/web/20160202113917/http://www.genengnews.com/gen-news-highlights/abbott-to-acquire-alere-for-5-8b/81252306/|url-status=live}}</ref><ref>{{cite web|url=https://www.bloomberg.com/news/articles/2016-02-01/abbott-to-buy-medical-diagnostics-maker-alere-for-56-a-share|title=Abbott's $5.8 Billion Deal for Alere Is Device Sector's Latest|author=Michelle Cortez|date=1 February 2016|publisher=Bloomberg L.P.|access-date=5 March 2017|archive-date=11 October 2016|archive-url=https://web.archive.org/web/20161011185155/http://www.bloomberg.com/news/articles/2016-02-01/abbott-to-buy-medical-diagnostics-maker-alere-for-56-a-share|url-status=live}}</ref> In January 2017, Abbott announced it would acquire [[St. Jude Medical]] for $25 billion (each share receiving $46.75 in cash & 0.8708 shares of Abbott common stock, equating to an approximate value of $85).<ref name=":0" /><ref>{{cite web|url=https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion|title=Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion|author=Michelle Cortez|date=28 April 2016|publisher=Bloomberg L.P.|access-date=5 March 2017|archive-date=7 March 2020|archive-url=https://web.archive.org/web/20200307111910/https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion|url-status=live}}</ref><ref>{{cite web|url=https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense|title=Abbott-St. Jude Combination: Why It Makes Sense|date=28 April 2016|publisher=Bloomberg L.P.|access-date=5 March 2017|archive-date=15 April 2017|archive-url=https://web.archive.org/web/20170415200817/https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense|url-status=live}}</ref> On 3 October 2017, the company closed the Alere acquisition making the surviving entity the market leader player in the $7 billion point-of-care diagnostic space within the broader $50 billion in-vitro diagnostics market with this takeover.<ref>{{cite web|url=http://www.nasdaq.com/article/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-cm854254|title=Abbott to Gain from Alere's Takeover Due for Oct 3 Closure|work=GEN|access-date=5 October 2017|archive-date=5 October 2017|archive-url=https://web.archive.org/web/20171005141211/http://www.nasdaq.com/article/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-cm854254|url-status=live}}</ref> With the acquisition of Alere, the company also obtained the subsidiary Arriva Medical, which is the largest mail-order diabetic supplier.{{citation needed|date=June 2020}} Arriva Medical announced business closure after Abbott acquisition effective 31 December 2017.<ref>{{cite web|url=http://www.hmenews.com/article/embattled-arriva-medical-closes|title=Embattled Arriva Medical closes|work=GEN|access-date=6 December 2017|archive-date=6 December 2017|archive-url=https://web.archive.org/web/20171206221738/http://www.hmenews.com/article/embattled-arriva-medical-closes|url-status=live}}</ref>

In 2017, the FDA approved Abbott's FreeStyle Libre glucose monitoring system, which reads glucose levels through a self-applied sensor without finger pricks.<ref>{{cite web|url=https://www.medicaldevice-network.com/news/newsfda-approves-abbotts-freestyle-libre-glucose-monitoring-system-5938126/|title=FDA approves Abbott's Freestyle Libre glucose monitoring system|website=Medical Device Network|date=29 September 2017|access-date=17 October 2019|archive-date=17 October 2019|archive-url=https://web.archive.org/web/20191017194312/https://www.medicaldevice-network.com/news/newsfda-approves-abbotts-freestyle-libre-glucose-monitoring-system-5938126/|url-status=live}}</ref>

In August 2018, Reuters reported that Abbott Laboratories was among the top five companies for branded generic drugs in Russia.<ref>{{cite news |title=Factbox: U.S. companies with exposure to Russia |url=https://www.reuters.com/article/us-usa-russia-sanctions-companies-factbo/factbox-u-s-companies-with-exposure-to-russia-idUSKBN1KU2L8 |work=Reuters |date=9 August 2018 |access-date=29 January 2019 |archive-date=1 December 2020 |archive-url=https://web.archive.org/web/20201201061738/https://www.reuters.com/article/us-usa-russia-sanctions-companies-factbo/factbox-u-s-companies-with-exposure-to-russia-idUSKBN1KU2L8 |url-status=live }}</ref>

[[File:ID Now testing (51038387158).jpg|thumb|Nucleic acid testing for COVID-19 conducted using an Abbott Laboratories ID Now device]]
In November 2018, Abbott received United States FDA clearance for FreeStyle LibreLink, a glucose reader [[smartphone app]].<ref>{{cite web|url=https://www.mobihealthnews.com/content/new-fda-clearance-abbott-freestyle-libre-users-can-ditch-handheld-readers-app|title=With new FDA clearance, Abbott Freestyle Libre users can ditch handheld readers for an app|website=Mobi Health News|date=November 2018|access-date=17 October 2019|archive-date=20 February 2020|archive-url=https://web.archive.org/web/20200220045000/https://www.mobihealthnews.com/content/new-fda-clearance-abbott-freestyle-libre-users-can-ditch-handheld-readers-app|url-status=live}}</ref>

In January 2019 purchased Cephea Valve Technologies, Inc. which is developing a less-invasive replacement heart valve for people with mitral valve disease.<ref>{{cite web|url=https://www.biospace.com/article/abbott-to-acquire-cephea-valve-technologies-inc-/|title=Abbott To Acquire Cephea Valve Technologies, Inc.|website=BioSpace|access-date=2 June 2019|archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820173325/https://www.biospace.com/article/abbott-to-acquire-cephea-valve-technologies-inc-/|url-status=live}}</ref>

In March 2020, Abbott received [[emergency use authorization]] (EUA) from the US FDA for a [[SARS-CoV-2]] test during the [[COVID-19 pandemic]].<ref>{{cite web|url=https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |title=FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits |date=19 March 2020 |website=International Business Times |archive-url=https://web.archive.org/web/20200320210743/https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |archive-date=20 March 2020 |url-status=live}}</ref> The tester is small (comparable to a small toaster), and produces results within 13 minutes.<ref>{{Cite web|url=https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/|title='A game changer': FDA authorizes Abbott Labs' portable, 5-minute coronavirus test the size of a toaster|last=Hauck|first=Grace|website=USA Today|language=en-US|access-date=2020-03-30|archive-date=28 April 2020|archive-url=https://web.archive.org/web/20200428170404/https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/|url-status=live}}</ref> Detroit received these tests on April 1, 2020.<ref>{{Cite news |url=https://www.washingtonpost.com/health/2020/04/01/scramble-rapid-coronavirus-tests-everybody-wants/ |title=The scramble for the rapid coronavirus tests everybody wants |last=Mufson |first=Steven |newspaper=The Washington Post |language=en |access-date=2020-04-02 |archive-date=10 February 2021 |archive-url=https://web.archive.org/web/20210210022633/https://www.washingtonpost.com/health/2020/04/01/scramble-rapid-coronavirus-tests-everybody-wants/ |url-status=live }}</ref><ref>{{Cite web |url=https://techcrunch.com/2020/04/01/detroit-to-be-first-to-deploy-abbott-labs-5-minute-covid-19-test-mayor-says/ |title=Detroit to be first to deploy Abbott Labs' 5-minute COVID-19 test, mayor says |last=Burns |first=Matt |website=TechCrunch |date=2 April 2020 |language=en-US |access-date=2020-04-02 |archive-date=17 July 2024 |archive-url=https://web.archive.org/web/20240717135224/https://techcrunch.com/2020/04/01/detroit-to-be-first-to-deploy-abbott-labs-5-minute-covid-19-test-mayor-says/ |url-status=live }}</ref> Also in March, the firm received EUA for a molecular COVID-19 test that runs on its m2000 RealTime lab-based platform.<ref>{{cite web|title=Abbott receives FDA emergency use authorization for coronavirus test|last=Newmaker|first=Chris|url=https://www.massdevice.com/abbott-receives-fda-emergency-use-authorization-for-coronavirus-test/|website=massdevice.com|access-date=13 April 2021|date=19 March 2020|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413192459/https://www.massdevice.com/abbott-receives-fda-emergency-use-authorization-for-coronavirus-test/|url-status=live}}</ref> In April 2020, itt received EUA from the FDA for its third COVID-19 test, an antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's ARCHITECT laboratory instruments.<ref name="medtechcorona">{{cite web|title=Abbott enters coronavirus antibody testing fray|last=Rachal|first=Maria|url=https://www.medtechdive.com/news/abbott-enters-coronavirus-antibody-testing-fray/576068/|website=medtechdive.com|date=15 April 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413192459/https://www.medtechdive.com/news/abbott-enters-coronavirus-antibody-testing-fray/576068/|url-status=live}}</ref> In May 2020, it received EUA from the FDA for another lab-based COVID-19 antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's Alinity i system.<ref name="medtechcorona" /><ref>{{cite web|title=Latest Abbott coronavirus antibody test receives FDA emergency use OK|last=Slabodkin|first=Greg|url=https://www.medtechdive.com/news/latest-abbott-coronavirus-antibody-test-receives-fda-emergency-use-ok/577667/|website=medtechdive.com|date=11 May 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201434/https://www.medtechdive.com/news/latest-abbott-coronavirus-antibody-test-receives-fda-emergency-use-ok/577667/|url-status=live}}</ref> Also in May, it received EUA from the FDA for a molecular COVID-19 test for use on the company's Alinity molecular laboratory instrument.<ref>{{Cite journal |last1=Perchetti |first1=Garrett A. |last2=Pepper |first2=Gregory |last3=Shrestha |first3=Lasata |last4=LaTurner |first4=Katrina |last5=Yae Kim |first5=Da |last6=Huang |first6=Meei-Li |last7=Jerome |first7=Keith R. |last8=Greninger |first8=Alexander L.|author8-link=Alexander L. Greninger |date=July 2021 |title=Performance characteristics of the Abbott Alinity m SARS-CoV-2 assay |journal=Journal of Clinical Virology |volume=140 |pages=104869 |doi=10.1016/j.jcv.2021.104869 |issn=1386-6532 |pmc=8118701 |pmid=34023572}}</ref><ref>{{cite web|title=Two Abbott COVID-19 tests receive EUA|last=Boyle|first=Annette|url=https://www.bioworld.com/articles/435056-two-abbott-covid-19-tests-receive-eua|website=bioworld.com|date=12 May 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201443/https://www.bioworld.com/articles/435056-two-abbott-covid-19-tests-receive-eua|url-status=live}}</ref>

In August 2020, Abbott received EUA from the FDA for its credit-card-sized $5, 15-minute, portable COVID-19 antigen test, BinaxNOW, compatible with the NAVICA mobile app.<ref>{{cite web|title=Abbott wins EUA for COVID-19 test that runs off a card|last=Newmarker|first=Chris|url=https://www.massdevice.com/breaking-abbott-wins-eua-for-covid-19-test-that-runs-off-a-card/|website=massdevice.com|date=27 August 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201432/https://www.massdevice.com/breaking-abbott-wins-eua-for-covid-19-test-that-runs-off-a-card/|url-status=live}}</ref><ref>{{cite news|title=This $5 rapid test is a potential game-changer in COVID-19 testing|url=https://abc7.com/binaxnow-binax-now-coronavirus-test-rapid/6391998/ |website=abc7.com|date=27 August 2020}}</ref>

In October 2020, Abbott received EUA from the FDA for its lab-based COVID-19 IgM antibody blood test.<ref>{{cite web|title=Abbott wins FDA EUA for COVID-19 IgM antibody test|last=Whooley|first=Sean|url=https://www.massdevice.com/abbott-wins-fda-eua-for-covid-19-igm-antibody-test/|website=massdevice.com|date=13 October 2020|access-date=14 April 2021|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.massdevice.com/abbott-wins-fda-eua-for-covid-19-igm-antibody-test/|url-status=live}}</ref> In December 2020, its rapid (20') antigen BinaxNOW COVID-19 test received EUA from the FDA for home use.<ref>{{Cite journal |last1=Perchetti |first1=Garrett A. |last2=Huang |first2=Meei-Li |last3=Mills |first3=Margaret G. |last4=Jerome |first4=Keith R. |author5-link=Alexander L. Greninger |last5=Greninger |first5=Alexander L. |date=2021-02-18 |editor-last=Loeffelholz |editor-first=Michael J. |title=Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag Card |journal=Journal of Clinical Microbiology |language=en |volume=59 |issue=3 |pages=e02880–20 |doi=10.1128/JCM.02880-20 |issn=0095-1137 |pmc=8106729 |pmid=33310764}}</ref><ref>{{cite web|title=Abbott Labs' at-home, $25 rapid COVID-19 test gets EUA from FDA|last=Kilgore|first=Tomi|url=https://www.marketwatch.com/story/abbott-labs-at-home-25-rapid-covid-19-test-gets-eua-from-fda-2020-12-16|website=marketwatch.com|date=16 December 2020|access-date=14 April 2021|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.marketwatch.com/story/abbott-labs-at-home-25-rapid-covid-19-test-gets-eua-from-fda-2020-12-16|url-status=live}}</ref> ''Forbes'' reported in January 2021 that the firm had delivered more than 400 million COVID-19 tests, 300 million in the fourth quarter of 2020.<ref>{{cite web|title=Abbott Profits Rise As Covid-19 Diagnostic Sales Eclipse 400 Million Tests|last=Japsen|first=Bruce|url=https://www.forbes.com/sites/brucejapsen/2021/01/27/abbott-profits-jump-as-covid-19-test-sales-surpass-400-million/?sh=7ad91257124a|website=Forbes|date=27 January 2021|access-date=14 April 2021|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.forbes.com/sites/brucejapsen/2021/01/27/abbott-profits-jump-as-covid-19-test-sales-surpass-400-million/?sh=7ad91257124a|url-status=live}}</ref>

In September 2021, Abbott acquired Walk Vascular, LLC.<ref>{{Cite web|url=https://www.biospace.com/article/releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc/?s=79|title=Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC|date=2 September 2021 |access-date=3 September 2021|archive-date=3 September 2021|archive-url=https://web.archive.org/web/20210903201150/https://www.biospace.com/article/releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc/?s=79|url-status=live}}</ref>

In January 2022, Abbott introduced Lingo, a line of consumer biowearable sensors that collects a range of biological readings to optimize exercise and nutrition regimens.<ref>{{cite news|url=https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech|author=Andrea Park|date=January 6, 2022|title=Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech|work=Fierce Biotech|access-date=23 January 2023|archive-date=23 January 2023|archive-url=https://web.archive.org/web/20230123191646/https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech|url-status=live}}</ref>

Following the 2022 Russian invasion of Ukraine, Abbott Laboratories continued its business operations in Russia while suspending non-essential activities such as new investments and advertising.<ref>{{Cite web |last=Varney |first=Sarah |date=2022-03-10 |title=Which Companies Aren't Exiting Russia? Big Pharma |url=https://kffhealthnews.org/news/article/big-pharma-reaction-russia-ukraine-war/ |access-date=2025-02-20 |website=KFF Health News |language=en-US}}</ref><ref>{{Cite web |title=Фармкомпании сворачивают операции в России в ответ на военную операцию в Украине |url=https://www.business-humanrights.org/ru/%D1%81%D0%B2%D0%B5%D0%B6%D0%B8%D0%B5-%D0%BD%D0%BE%D0%B2%D0%BE%D1%81%D1%82%D0%B8/%D1%84%D0%B0%D1%80%D0%BC%D0%BA%D0%BE%D0%BC%D0%BF%D0%B0%D0%BD%D0%B8%D0%B8-%D1%81%D0%B2%D0%BE%D1%80%D0%B0%D1%87%D0%B8%D0%B2%D0%B0%D1%8E%D1%82-%D0%BE%D0%BF%D0%B5%D1%80%D0%B0%D1%86%D0%B8%D0%B8-%D0%B2-%D1%80%D0%BE%D1%81%D1%81%D0%B8%D0%B8-%D0%B2-%D0%BE%D1%82%D0%B2%D0%B5%D1%82-%D0%BD%D0%B0-%D0%B2%D0%BE%D0%B5%D0%BD%D0%BD%D1%83%D1%8E-%D0%BE%D0%BF%D0%B5%D1%80%D0%B0%D1%86%D0%B8%D1%8E-%D0%B2-%D1%83%D0%BA%D1%80%D0%B0%D0%B8%D0%BD%D0%B5/ |access-date=2025-02-20 |website=Business & Human Rights Resource Centre |language=ru}}</ref> Research from [[Yale School of Management]] evaluating corporate responses to the invasion placed Abbott in the "Buying Time" category with a "Grade D" rating, indicating that it postponed future investments and marketing while continuing substantive business in Russia.<ref>{{Cite web |title=Over 1,000 Companies Have Curtailed Operations in Russia—But Some Remain {{!}} Yale School of Management |url=https://som.yale.edu/story/2022/over-1000-companies-have-curtailed-operations-russia-some-remain |access-date=2025-02-20 |website=som.yale.edu |language=en}}</ref>

In May 2022, Abbott received 510(k) clearance from the FDA for FreeStyle Libre 3, the latest version of its continuous glucose monitor.<ref>{{cite news|url=https://www.medtechdive.com/news/abbott-libre-3-CGM-fda-clearance/624591/|author=Nick Paul Taylor|date=May 31, 2022|title=Abbott's Libre 3 glucose monitor gets FDA clearance as CGM market intensifies|work=MedTechDive|access-date=29 December 2022|archive-date=29 December 2022|archive-url=https://web.archive.org/web/20221229030224/https://www.medtechdive.com/news/abbott-libre-3-CGM-fda-clearance/624591/|url-status=live}}</ref>

In August 2022, Abbott received FDA approval for Proclaim Plus, a multi-use spinal cord stimulation system designed to target chronic pain. The Proclaim Plus system is capable of treating six independent pain sites and has a recharge-free battery life of up to 10 years.<ref>{{cite news|url=https://www.fiercebiotech.com/medtech/abbott-proclaims-fda-approval-neurostimulator-treat-pain-six-areas-once#:~:text=Abbott%20proclaims%20FDA%20approval%20of,in%206%20areas%20at%20once&text=A%20spinal%20cord%20stimulation%20device,of%20the%20body%20at%20once|author=Andrea Park|date=August 23, 2022|title=Abbott proclaims FDA approval of neurostimulator to treat pain in 6 areas at once|work=Fierce Biotech|access-date=23 January 2023|archive-date=23 January 2023|archive-url=https://web.archive.org/web/20230123190313/https://www.fiercebiotech.com/medtech/abbott-proclaims-fda-approval-neurostimulator-treat-pain-six-areas-once#:~:text=Abbott%20proclaims%20FDA%20approval%20of,in%206%20areas%20at%20once&text=A%20spinal%20cord%20stimulation%20device,of%20the%20body%20at%20once|url-status=live}}</ref>

In October 2022, Abbott received EUA from the FDA for its real-time [[Polymerase chain reaction|PCR]] test Alinity m MPXV; this marks the first FDA emergency authorization for commercial monkeypox testing.<ref>{{cite news|url=https://www.medtechdive.com/news/abbott-eua-fda-monkeypox-test/633667/|author=Nick Paul Taylor|date=October 10, 2022|title=Abbott lands FDA emergency authorization for first commercial monkeypox test|work=MedTechDive|access-date=29 December 2022|archive-date=29 December 2022|archive-url=https://web.archive.org/web/20221229024014/https://www.medtechdive.com/news/abbott-eua-fda-monkeypox-test/633667/|url-status=live}}</ref>

On July 5, 2023, Abbott received approval from the FDA for its leadless pacemaker system Aveir DR.<ref name="aveirdr" /> In August, the company announced it would acquire Bigfoot Biomedical.<ref>{{cite web | url=https://www.biospace.com/article/releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes/?s=79 | title=Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes | date=5 September 2023 | access-date=7 September 2023 | archive-date=7 September 2023 | archive-url=https://web.archive.org/web/20230907113323/https://www.biospace.com/article/releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes/?s=79 | url-status=live }}</ref>

Today, Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide.<ref>{{citation|author=Baker Batte|title=Study finds quick way of testing for hepatitis B|date=27 June 2019|url=https://observer.ug/lifestyle/61182-study-finds-quick-way-of-testing-for-hepatitis-b|access-date=3 April 2020|archive-date=5 October 2022|archive-url=https://web.archive.org/web/20221005032245/https://observer.ug/lifestyle/61182-study-finds-quick-way-of-testing-for-hepatitis-b|url-status=live}}</ref><ref>{{cite web | url=https://www.coreties.com/consignees/abbott-laboratories-int-l-llc | title=Abbott Laboratories Importer Profile: Shipment Insights and Market Trends | access-date=21 July 2024 | archive-date=21 July 2024 | archive-url=https://web.archive.org/web/20240721002138/https://www.coreties.com/consignees/abbott-laboratories-int-l-llc | url-status=live }}</ref>

===Acquisition history===
{{hidden begin|border=1px  #aaa solid|title=Abbott Laboratories Acquisitions|ta1=center}}
{{Tree list}}
* '''Abbott Laboratories''' <small>(Est. 1885, Abbott Alkaloidal Company)</small>
** Ross Laboratories <small>(Acq 1964)</small>
** SmithKline Beecham <small>(Acq 1982, later sold)</small>
** [[BASF|Knoll]] <small>(Acq 2001)</small>
** [[Selsun Blue]] <small>(Sold to [[Chattem]] 2002)</small>
** Murine <small>(Sold to [[Prestige Brands]] 2002)</small>
** Clear Eyes <small>(Sold to [[Prestige Brands]] 2002)</small>
** i-STAT <small>(Acq 2004)</small>
** TheraSense <small>(Acq 2004)</small>
** [[Guidant|Guidant (vascular device division)]] <small>(Acq 2006)</small>
*** IntraLase Corp <small>(Acq 2007)</small>
** [[Advanced Medical Optics]] <small>(Acq 2009)</small>
** Solvay Pharmaceuticals <small>(Acq 2010)</small>
** [[STARLIMS]] <small>(Acq 2010)</small>
*** Lab Data Management Ltd <small>(Acq 2008)</small>
** IDEV Technologies <small>(Acq 2013)</small>
** OptiMedica Corporation <small>(Acq 2013)</small>
** Veropharm <small>(Acq 2014)</small>
** Topera, Inc <small>(Acq 2014)</small>
** Kalo Pharma Internacional S.L. <small>(Acq 2014)</small>
*** [[CFR Pharmaceuticals]]
** [[Tendyne Holdings Inc.]] <small>(Acq 2015)</small>
** [[Alere]] <small>(Acq 2016)</small>
*** Epocal, Inc. <small>(Acq 2013)</small>
*** Arriva Medical <small>(Acq 2012)</small>
** [[St. Jude Medical]] <small>(Est 1976, Acq 2016)</small>
*** Pacesetter, Inc. <small>(Acq 1994)</small>
*** Daig Corporation <small>(Acq 1996)</small>
*** Heart Valve Company <small>(Acq 1996)</small>
*** Biocor Industria <small>(Acq 1996)</small>
*** Ventritex <small>(Acq 1997)</small>
***  [[Tyco International|Tyco International (Angio-Seal division)]] <small>(Acq 1999)</small>
*** Endocardial Solutions <small>(Acq 2005)</small>
*** Advanced Neuromodulation Systems <small>(Acq 2005)</small>
*** MediGuide <small>(Acq 2008)</small>
*** AGA Medical <small>(Acq 2010)</small>
*** LightLab Imaging <small>(Acq 2010)</small>
*** Nanostim Inc <small>(Acq 2013)</small>
*** Endosense <small>(Acq 2013)</small>
*** CardioMEMS Inc. <small>(Acq 2014)</small>
*** Spinal Modulation <small>(Acq 2015)</small>
*** [[Thoratec Corporation]] <small>(Acq 2015)</small>
**** Apica Cardiovascular Limited <small>(Acq 2014)</small>
**** Levitronix (Medical division) <small>(Acq 2011)</small>
**** [[Getinge Group|Getinge Group (Heat pump technology division)]] <small>(Acq 2014)</small>
**** Thermo Cardiosystems <small>(Acq 2010)</small>
** Cephea Valve Technologies, Inc. <small>(Acq 2019)</small>
** Walk Vascular, LLC <small>(Acq 2021)</small>
** Cardiovascular Systems, Inc. <small>(Acq 2023)</small>
** [[Bigfoot Biomedical]] <small>(Acq 2023)</small>{{Tree list/end}}
{{hidden end}}